(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 March 2014 (13.03.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/038682 A2

(51) International Patent Classification:
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/JP2013/074172

(22) International Filing Date:
3 September 2013 (03.09.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2012-193757 4 September 2012 (04.09.2012) JP

(71) Applicants: **NIIGATA UNIVERSITY** [JP/JP]; 8050, Ikarashi 2-no-cho, Nishi-ku, Niigata-shi, Niigata, 9502181 (JP). **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors: **KAGAMU, Hiroshi**; c/o NIIGATA UNIVERSITY, 1-757, Asahi-machi-dori, Chuo-ku, Niigata-shi, Niigata, 9518585 (JP). **NARITA, Ichiei**; c/o NIIGATA UNIVERSITY, 1-757, Asahi-machi-dori, Chuo-ku, Niigata-shi, Niigata, 9518585 (JP). **GOTO, Yoshihiro**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **HAYASHI, Takashi**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(74) Agent: **SAEGUSA & PARTNERS**; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5410045 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/038682 A2

(54) **Title**: CANCER DIAGNOSTIC AND THERAPEUTIC METHOD TARGETING MOLECULES EXPRESSED IN CANCER STEM CELLS

(57) **Abstract**: The present invention provides a novel method for determining cancer malignancy, a novel cancer diagnostic method, a novel method for determining prognosis, a novel vaccine for cancer treatment, and a novel vaccine for suppressing cancer metastasis. Specifically, the invention provides a cancer malignancy evaluation method that comprises the step of measuring a DDX3X expression level in a cancer tissue, and the step of evaluating malignancy of the cancer tissue by using the DDX3X expression level.